Biotech | January 10, 2022
Novavax and Serum file EUA for Covovax in South Africa
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
Subscribe To Our Newsletter & Stay Updated
